FECH Expression Correlates with the Prognosis and Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma

Table 1

Relationship between FECH expression and clinicopathological characteristics in patients with ccRCC.

Characteristic	Low expression of FECH	High expression of FECH
n	269	270
T stage, n (%)			<0.001
T1	107 (19.9%)	171 (31.7%)
T2	42 (7.8%)	29 (5.4%)
T3	116 (21.5%)	63 (11.7%)
T4	4 (0.7%)	7 (1.3%)
N stage, n (%)			1.000
N0	125 (48.6%)	116 (45.1%)
N1	8 (3.1%)	8 (3.1%)
M stage, n (%)			0.009
M0	202 (39.9%)	226 (44.7%)
M1	50 (9.9%)	28 (5.5%)
Pathologic stage, n (%)			<0.001
Stage I	105 (19.6%)	167 (31.2%)
Stage II	32 (6%)	27 (5%)
Stage III	79 (14.7%)	44 (8.2%)
Stage IV	51 (9.5%)	31 (5.8%)
Primary therapy outcome, n (%)			0.177
PD	8 (5.4%)	3 (2%)
SD	2 (1.4%)	4 (2.7%)
PR	1 (0.7%)	1 (0.7%)
CR	52 (35.4%)	76 (51.7%)
Gender, n (%)			0.547
Female	89 (16.5%)	97 (18%)
Male	180 (33.4%)	173 (32.1%)
Race, n (%)			0.533
Asian	3 (0.6%)	5 (0.9%)
Black or African American	32 (6%)	25 (4.7%)
White	232 (43.6%)	235 (44.2%)
Age, n (%)			0.413
≤60	129 (23.9%)	140 (26%)
>60	140 (26%)	130 (24.1%)
Histologic grade, n (%)			<0.001
G1	3 (0.6%)	11 (2.1%)
G2	104 (19.6%)	131 (24.7%)
G3	103 (19.4%)	104 (19.6%)
G4	54 (10.2%)	21 (4%)
Serum calcium, n (%)			0.219
Elevated	8 (2.2%)	2 (0.5%)
Low	106 (29%)	97 (26.5%)
Normal	85 (23.2%)	68 (18.6%)
Hemoglobin, n (%)			0.038
Elevated	5 (1.1%)	0 (0%)
Low	147 (32%)	116 (25.3%)
Normal	94 (20.5%)	97 (21.1%)
OS event, n (%)			<0.001
Alive	158 (29.3%)	208 (38.6%)
Dead	111 (20.6%)	62 (11.5%)
Laterality, n (%)			0.734
Left	128 (23.8%)	124 (23%)
Right	140 (26%)	146 (27.1%)
Age, median (IQR)	61 (54, 70)	60 (50, 69)	0.144